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Background. Alzheimer’s disease (AD) is a common health condition affecting senile people and leads to severe cognitive dysfunctions.
Acupuncture has been shown to be a possible alternative natural remedy for AD in some animal studies. Objective. To perform a
systematic review to identify the effect of verum-acupuncture compared with sham-acupuncture on learning andmemory performance
among animalmodels of AD.Methods. Experimental animal studies of treatingADvia verum- and sham- acupuncture were searched in
nine electronic databases, including Sciverse ScienceDirect, PubMed, Springer, Ebsco Medline, AMED, EMBASE (Elsevier), Scopus
(Elsevier), PsycINFO (ProQuest), and OVID from the dates of the databases’ inception to June 2019. +e Morris water maze test was
considered as an outcomemeasure.+e software Revman 5.3 and Stata 16.0 were used to conduct the meta-analysis. Heterogeneity was
examined by using I2 statistics. +e publication bias was assessed via Begg’s test by Stata 16.0. Results. Twelve studies involving 229
animals met the inclusion criteria. Most of the studies had amoderate quality according to SYRCLE’s risk of bias tool for animal studies.
+e results of the meta-analysis indicated that verum-acupuncture could reduce the escape latency (MD� −12.90, 95% CI (−17.08,
−8.71), p< 0.001) and increase the time spent in the original platform quadrant (MD� 7.28, 95% CI (4.23, 10.33), p< 0.001) and
frequency of the crossing former platform (MD� 2.01, 95% CI (1.53, 2.50), p< 0.001) compared with the sham-acupuncture. Con-
clusions. Acupuncture is effective in improving cognitive functions in AD animal models, and this benefit is more than just a placebo
effect. Further clinical trials are needed to confirm the findings.
1. Background and Introduction
Alzheimer’s disease (AD) is one of the most important
causes of dementia [1], contributing to more than 60% of all
cases [2, 3]. As a progressive neurodegenerative disorder
without efficient therapeutic agents, AD irreversibly and
progressively impairs memory, language, thinking, and
other critical mental functions [4, 5]. A report from WHO
estimated that dementia contributed 11.2% of years spent
living with a disability in those aged 60 years and above,
which is more than cancer, cardiac vascular disease, and
stroke [6]. Disability and dependence due to AD then further
place a burden on caregivers [7]. Because of a high preva-
lence, AD has an enormous socioeconomic impact. In 2017,
an estimated 18.4 billion hours and valued at over $232
billion of care was provided to patients of AD or other
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dementias by over 16 million family members and other
unpaid caregivers [8]; in 2018, approximately $277 billion
was paid for health care, long-term care, and hospice services
for the senior over 65-year-old with dementia [8]. +e
number of cases was even predicted to affect 1 in 85 indi-
viduals worldwide by 2050 [9]. Furthermore, the countries/
regions with the greatest number of affected individuals are
China and the developing western Pacific, Western Europe,
and the US [10]. With the globally speedy increase in the
aging population, AD represents one of the great public
health challenges of the 21st century [11] and deserves much
more attention.
No ideal treatment for AD is available today [12].
+ough some interventions including currently prevailing
medication regimens are likely to improve symptoms
temporarily, it cannot stop or reverse the progression of AD
either [12]. Cholinesterase inhibitors (ChEIs) are commonly
used in the clinical practice. Donepezil, galantamine, and
rivastigmine are a class of medications that are currently
approved by the US Food and Drug Administration (FDA)
for treating patients in the mild to moderate stage of AD
[13, 14]. FDA has also approved a daily use of 23mg
donepezil compound to treat the symptoms of moderate to
severe AD [15]. Nevertheless, raised costs and increased risk
of serious adverse events linked to ChEIs treatment has been
challenged [16]. For instance, adverse reactions including
insomnia, nausea, and diarrhea may already occur with just
10mg/d of donepezil [17], let alone the incidence of riva-
stigmine-induced adverse events found even higher than
that of donepezil [18]. Memantine is another FDA-approved
medication for moderate to severe AD but is also limited to
the increased risk for a variety of adverse effects such as
somnolence, hypertension, weight gain, and confusion [19].
Due to the acute health risk of AD and the limitations of
pharmacotherapy, there have been multiple anecdotal re-
ports and controlled studies over the past decade to examine
the effectiveness of acupuncture on AD. Acupuncture is an
integral part of traditional Chinese medicine with consid-
erable clinical efficacy and minimal side effects [20] that can
be traced back for at least 4000 years [21]. It is a technique of
skin being inserted and penetrated with the thin, solid, and
metallic needles that are manipulated by the hands (manual
acupuncture, MA) or by electrical stimulation (electro-
acupuncture, EA). +e entire TCM model for the action of
acupuncture is that balanced Yin and Yang and Qi, along
with blood and body fluid is vital to optimal health, whereas
any imbalance or interruption of the homeostasis would
result in illness and diseases [21]. In many East Asian
countries including China, Japan, Korea, as well as some
regions in the US and Europe, acupuncture is popular and
has been extensively used for multiple neurodegenerative
diseases including AD [12], while the therapeutic effect is
inconclusive. A systematic review published in 2009 implied
insufficient evidence to prove acupuncture was effective on
both cognitive function and activities of daily living (ADL)
among patients with AD [22]. However, another systematic
meta-analysis published in 2015 suggested that acupuncture
was not only more effective than drugs but also might
further enhance the effects of drugs in improving both
cognitive function and ADL [23]. Additionally, there is still
hot debate whether acupuncture is merely a psychological or
“placebo” effect, accompanied with both positive and neg-
ative reports published again and again [24–26].
Animal study is often used to examine the efficacy of
acupuncture as the factors that might interfere with the results
can be well controlled in the study. Findings from some
animal studies have shown that acupuncture might be ben-
eficial for AD [27–29]. However, there has been no systematic
review concerning acupuncture treatment on AD animals. In
fact, a systematic review based on animal data might inform
the planning and promote the likelihood of success of future
clinical trials, preclude unnecessary study replication, identify
what is valuable in further research, and elucidate the un-
derling mechanism of acupuncture [30]. +us, we aimed to
evaluate the effectiveness of verum-acupuncture compared
with sham-acupuncture on cognitive dysfunctions in AD
animals. We choose studies with sham-acupuncture as the
control because it is a better way to address the psychological
or “placebo” effects of acupuncture.
2. Materials and Methods
We formulated the research question “Is the verum-acu-
puncture more likely to attenuate the cognitive dysfunction
in AD animals when compared to sham-acupuncture
therapy?” +is guiding question was defined by the PICO
strategy. In order to address this question, we investigated
and assessed AD animals (P� participants) treated with
verum-acupuncture therapy (I � intervention) and com-
pared with those AD animals receiving sham-acupuncture
therapy (C� intervention comparison or control), aiming
at verifying the changes in learning and memory functions
reflected by Morris water maze (O � outcome).
2.1. Search Strategy and Eligibility Criteria. We searched the
following nine English electronic databases: Sciverse Science-
Direct, PubMed, Springer, Ebsco Medline, AMED, EMBASE
(Elsevier), Scopus (Elsevier), PsycINFO (ProQuest), andOVID
in June 2019, using the combined terms “(electroacupuncture,
acupuncture, meridian, or acupoint) and (dementia or Alz-
heimer).” +e retrieval was conducted with no restrictions
regarding the year, but the language was limited to English.We
also tried to identify additional studies from other source,
including the reference list of the included papers and those
grey literatures such as conference papers and unpublished
papers. Two independent reviewers were responsible for the
literatures searching work and quality evaluation. +e detailed
search strategy is shown in Appendix 1.
2.2. Inclusion and Exclusion Criteria
2.2.1. Inclusion Criteria
(1) P: AD model animals
(2) I: the acupuncture therapy was limited to only MA
and EA
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(3) C: intervention in the control group was limited to
only sham-acupuncture therapy
(4) O: the cognitive performance of AD animals was
reflected by results of the Morris water maze test
(outcome indicators such as escape latency, time
spent in the quadrant in which the former platform
was located, frequency of crossing through the
former platform, and swimming speed)
(5) Language: only studies published in English
(6) No publication date limit was set, and the literature
retrieval work was conducted in June 2019
2.2.2. Exclusion Criteria
(1) +e acupuncture therapy was laser acupuncture,
auricular acupuncture, or other acupuncture
techniques
(2) Studies that only compared different acupuncture
techniques/acupoints or only compared the different
intervention frequencies within the same acupunc-
ture technique
(3) Studies that only compared acupuncture with TCM/
western medication or only compared a combo-
therapy of acupuncture and TCM/western medica-
tion with either acupuncture or TCM/western
medication
(4) Studies that had no control group or the intervention
in the control group was wait-list control (AD animal
without any therapy) or western medication control
(5) Duplicate articles (if multiple literature reports were
judged to be the same experiment, the one with the
largest sample size and the most comprehensive
information was retained)
2.3. Data Extraction. EndNote software (Version X7) was
used to store the results of the searches and to remove
duplicates. One researcher (ZFY) generated the search
strategy, searched the potential databases, and drew up a list
of all the records. Two evaluators (ZFY and FQQ) inde-
pendently evaluated and screened the articles according to
the inclusion and exclusion criteria. Disagreements were
solved together through discussion with a third reviewer
(SHL). Two reviewers (ZFY and FQQ) independently
extracted the data and proofread the information.
+e following data were extracted: the last name of the
first author, publication year, the species, gender, age, weight
range, and numbers of the included animals, modeling
methodology of AD, approach of treatment with timing and
frequency in the verum-acupuncture and control groups, the
acupoints used, subtest indicators selected in the Morris
water maze test, the results of each study (positive or
negative), and the underlying mechanism of acupuncture.
+e final outcomes were extracted if several outcomes were
presented. When the outcome data were only shown
graphically, we attempted to contact the authors to obtain
the original and detailed data; if we received no response to
our request, GetData Graph Digitizer software (Version
2.25) was used to measure the data.
2.4. Risk of Bias Assessment. A ten-item checklist introduced
by “SYRCLE’s risk of bias tool for animal studies” [31] was
used to assess the study quality.+e quality of each study was
evaluated by the judgment of “Yes,” “No,” or “Unclear.”
“Yes” judgment indicated a low risk of bias; “No” judgment
indicated high risk of bias; “Unclear” judgment was sug-
gested if insufficient details had been reported to evaluate the
risk of bias properly. Each study could score ranging from
zero to ten, with a high score represented a superior quality.
+e assessment was done by two independent reviewers
(ZFY and FQQ), and disagreements were solved through
consensus-oriented discussion or by consulting a third re-
searcher (SHL).
3. Statistical Analysis
Meta-analysis was performed by Revman software (Version
5.3) to assess the effectiveness of the therapy. As the major
outcomes were continuous variables, the mean± standard
deviation (mean± SD) was calculated with 95% confidence
interval (CI). Level of heterogeneity across the studies was
tested using the Q-test and I2 test. +e results were pooled
using a fixed effects model when the p value was >0.10 in the
Q-test and the I2 value was ≤50%. Otherwise, a random
effects model was applied. When significant heterogeneity
existed, the subgroup analysis was further conducted to
measure the pooled effect and to explore the source of
heterogeneity based on animal species, acupuncture
methods, and modeling methods. Sensitivity analyses and
metaregressions were adopted to explore the source of
heterogeneity if possible as well. +e publication bias was
assessed via Egger’s test and Begg’s test by Stata software
(Version 16.0).
4. Results
3282 possibly relevant studies were identified in the initial
search. After removing the duplicates, we screened the titles
and the abstracts of 1426 remaining records, and 1376
records were excluded. For further screening, 50 full-text
articles were downloaded. Eventually, 12 studies met the
inclusion criteria. +e selection process flow diagram is
shown in Figure 1.
4.1. Study Characteristics. Characteristics of all the 12 in-
cluded studies are listed in Table 1.
4.1.1. Species, Characteristics, and Features of the Animal.
+e 12 studies included 229 ADmodel animals, 115 of which
were in an acupuncture group and 114 of which were in a
sham-acupuncture group. Among the 229 animals, there
were 189 males and 20 females, while 1 study involved a total
of 20 animals but did not indicate the gender of them [28].
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Of the 12 studies, rats were used in four studies, in-
cluding SD rats used in two studies [29, 38] and Wistar rats
used in two studies [34, 35]. +e remaining studies adopted
mice for modeling, including three studies adopted APP/PS1
double transgenic mice [28, 33, 40], and the rest used
SAMP8 mice.
Nearly, all 12 studies mentioned the age of the experi-
mental animals except for one study [40]. In mice-related
studies, the age of mice ranged from 3 to 12 months; in rats-
related studies, the age range was from 2 to 5 months.
Meanwhile, 6 studies mentioned the weight of the experi-
mental animals [29, 33–35, 38, 40]. +e weight ranges were
20–27 grams in mice models and 220–350 grams in rat
models.
4.1.2. Model Preparation Methods. Different approaches
were used to establish an AD animal model in rats and mice.
In the four rats models, intraperitoneal injection of sco-
polamine (SCO) was used to establish an AD model in one
study [29] and intracerebroventricular (ICV) injection of
Aβ1–42 was used in two studies [34, 35], and the ICV in-
jection of Aβ1–40 was used in the rest one study [38]. In mice
models, three studies adopted APP/PS1 double transgenic
mice model [28, 33, 39], and the rest used SAMP8 mice
model as mentioned above [27, 32, 36, 37, 40].
4.1.3. Acupoints Selections. Acupoints selection is one of the
critical factors affecting the efficacy during acupuncture
practice [41].
+e frequency of acupoints used in the 12 included
studies was sorted out and listed as follows (Table 2).
Furthermore, the selection of acupoints is arranged in
descending order of times and frequency of use. As can be
seen, the most frequently used acupoint was GV20. In view
of the basic theory of TCM, due the special location of GV20,
which is on the vertex of the head where all the Yang me-
ridians meet [42], stimulating GV20 could clear the mind
and improve mental function [43]. In addition, CV6, CV12,
CV17, SP10, and ST36 were used as a set of acupoints in five
included studies to strengthen the foundation of Qi. Other
used acupoints included BL23 and TE4.
4.2. Study Quality Evaluation. +e quality assessments of 12
included papers are illustrated in Tables 3 and 4, and the
score of the study quality ranged from 2 to 8 out of a total 10
points.
Records identified through
database searching (n = 3,282):
1. Sciverse ScienceDirect (n = 31,250)
2. PubMed (n = 147)
3. Springer (n = 960)
4. Ebsco Medline (n = 38)
5. AMED (n = 7)
6. EMBASE (Elsevier) (n = 396)
7. Scopus (Elsevier) (n = 255)
8. PsycINFO (ProQuest) (n = 32)
9. OVID (n = 197)
Additional records identified
through other sources (n = 0)
Records after duplicates were removed (n = 1,426)
Records screened (n = 1,426)
Records excluded based on titles and
abstracts (n = 1376):
1. Not an animal experiment (n = 1355)
2. Case report, review, or data mining
analysis (n = 21) 
Records excluded full-text articles
assessed for eligibility (n = 50) Full-text articles excluded, with reasons
(n = 38)
1. No sham-acupuncture control (n = 22)
2. LA therapy (n = 1)
3. Y-maze test (n = 3)
4. Jump-platform test (n = 1)
5. No behavioral test (n = 8)
6. Republication (n = 3)
Studies included in qualitative
synthesis (n = 12) 
Studies included in quantitative
synthesis (meta-analysis) (n = 11)
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Figure 1: Flow diagram of the study selection process.
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Among the 12 studies, only two studies described the
specific random method [37, 39]. Similarly, only two studies
clearly showed that the baseline characteristics had been
evaluated or adjusted among the groups before the inter-
vention [35, 39], and two studies reported that caregivers or
investigators were blinded during the study [29, 33], respec-
tively. No study clarified if allocation was adequately concealed
and what randomization technique was applied in the trial.
Expected outcomes were comprehensively reported in all the
studies, and no study was identified with other problems that
could result in high risk of bias.
4.3.OutcomesAnalyses ofMorrisWaterMaze. Among the 12
studies, one study [40] adopted and measured total travelled
distance, line crossover number, and frequency of entries to
the IL zone as the subtest outcomes of Morris water maze,
which were different from other studies. +erefore, this
study was only included for descriptive analysis, while the
remaining studies were included for a meta-analysis, and the
results were illustrated as follows.
4.3.1. Escape Latency. Eleven studies [27–29, 32–39]
adopted escape latency as an outcome indicator, and all
reported a positive effect of verum-acupuncture in reducing
escape latency. However, there was a high heterogeneity
among the studies (p< 0.00001, I2 � 84%), and random ef-
fects model thereby was performed for analysis. According
to the results, there was a significant difference between
verum-acupuncture and sham-acupuncture in reducing
escape latency (MD� −12.90, 95% CI (−17.08, −8.71),
p< 0.00001) (Figure 2).
Due to the heterogeneity, we further conducted sub-
group analysis according to animal species (mice or rats),
modeling methods (SAMP8 and APP/PS1, intraperitoneally
injected with SCO, ICV Aβ1–42, or ICV Aβ1–40), and dif-
ferent acupuncture therapies (MA or EA). +e results are
showed as follows (Table 5).
Subgroup Analyses of Escape Latency
(a) Animal species: compared with sham - acupuncture,
verum-acupuncture could reduce the escape latency
in both mice (MD� −11.03, 95% CI (−15.31, −6.74),
p< 0.00001) and rats (MD� −16.74, 95% CI (−27.74,
−5.75), p � 0.003). Neither the mice (I2 � 79%) nor
the rats (I2 � 88%) observed a striking decline in
heterogeneity through this subgroup analysis.
(b) Acupuncture methods: compared with sham-acu-
puncture, both verum-MA and verum-EA could
decrease the escape latency (MD� –12.85, 95% CI
(–20.63, –5.07), p � 0.001 in MA; MD� –12.96, 95%
CI (–18.29, –7.63), p< 0.001 in EA). +e subgroup
analysis found that MA had mildly reduced het-
erogeneity (I2 � 66%), while EA did not (I2 � 90%).
(c) Modeling methods: compared with sham-acupunc-
ture, verum-acupuncture significantly shortened the
escape latency in SAMP8 (MD� −9.51, 95% CI
(−15.28, −3.73), p � 0.001), APP/PS1 (MD� −12.03,
95% CI (−18.19, −5.86), p � 0.0001), intraperitoneally
injected with SCO (MD� −25.59, 95% CI (−35.88,
−15.29), p< 0.00001), ICV Aβ1–40 (MD� −8.03, 95%
CI (−14.77, −1.28), p � 0.02), but not in ICV Aβ1–42
(MD� −17.21, 95% CI (−37.35, 2.94), p � 0.09). No
subgroup analysis based on modeling methods re-
duced heterogeneity except for SAMP8 (I2 � 26%).
4.3.2. Platform Crossover Numbers. Platform crossover
numbers were adopted as an outcome in eight studies
[27, 28, 33–35, 37–39], and all of these studies reported the
positive effect of verum-acupuncture in increasing platform
crossover numbers. However, there was a heterogeneity
among the studies (p< 0.00001, I2 � 91%) and random
Table 2: Frequency of acupoints used in studies.
Frequency, n (%) Acupoints Involved studies
7 (58.33) GV20 [28, 29, 33–35, 38, 39]
5 (41.67)
CV6
[27, 32, 36, 37, 40]
CV12
CV17
SP10
ST36
3 (25.00) BL23 [34, 35, 38]
1 (8.33) TE4 [29]
Abbreviations. BL23, Shenshu; CV6, Qihai; CV12, Zhongwan; CV17,
Danzhong; GV20, Baihui; SP10, Xuehai; ST36, Zusanli; TE4, Yangji.
Table 3:Methodological quality assessment of the included studies.
Study 1 2 3 4 5 6 7 8 9 10 Scores
Zhao et al. [27] U N U Y U U Y Y Y Y 5
Lin et al. [28] U N U Y U N Y Y Y Y 5
Lee et al. [29] U N U Y Y U Y Y Y Y 6
Li et al. [32] U N U Y U N Y Y Y Y 5
Lin et al. [33] U N U Y Y U Y Y Y Y 6
Yu et al. [34] U N U Y U U Y Y Y Y 5
Li et al. [35] U Y U Y U N Y Y Y Y 6
Zhao et al. [36] U N U Y U N Y Y Y Y 5
Luo et al. [37] Y N U Y U N Y Y Y Y 6
Guo et al. [38] U N U Y U U Y Y Y Y 5
Liu et al. [39] Y Y U Y U U Y Y Y Y 7
Li et al. [40] U N U Y U N Y Y Y Y 5
Notes. (1) Generation of animal allocation sequence was random; (2) each
group was similar or was at adjusted at baseline; (3) the allocation was
adequately concealed; (4) animals were housed at random; (5) both animal
breeders and researchers were blinded for the intervention of each animal
received; (6) animals were selected randomly for outcome evaluation; (7)
outcome evaluator was blinded; (8) the incomplete outcome data were
absolutely addressed; (9) reports of the research were free of selective
outcome reporting; (10) study was evidently free of other potential issues
which may cause bias. Y, yes (low-risk bias); N, no (high risk bias); U,
unclear.
Table 4:Methodological quality assessment of the included studies.
Study quality scores Studies n (%)
7 [40] 1 (8.33)
6 [29, 33, 35, 37] 4 (33.33)
5 [27, 28, 32, 34, 36, 38, 40] 7 (58.33)
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effects model thereby was used for analysis. A significant
difference was found between verum- and sham-acupunc-
ture in increasing platform crossover numbers (MD� 2.01,
95% CI (1.53, 2.50), p< 0.00001) (Figure 3).
Because of the high heterogeneity, we further conducted
subgroup analysis according to animal species (mice or rats),
modeling methods (SAMP8, APP/PS1, ICV Aβ1–42, or ICV
Aβ1–40), and different acupuncture therapies (MA or EA).
+e results are illustrated as follows (Table 6).
Subgroup Analyses of Platform Crossover Numbers
(a) Animal species: compared with sham-acupuncture,
verum-acupuncture increased the platform cross-
over numbers in bothmice (MD� 1.53, 95%CI (1.16,
1.89), p< 0.00001) and rats (MD� 3.29, 95%CI (1.47,
5.11), p � 0.0004). +e subgroup analysis observed
that mice had slightly reduced heterogeneity
(I2 � 84%), while rats did not (I2 � 91%).
(b) Acupuncture methods: compared with sham-acu-
puncture, verum-acupuncture showed more eleva-
tion in platform crossover numbers in both MA
(MD� 0.69, 95% CI (0.17, 1.21), p � 0.009) and EA
(MD� 2.40, 95% CI (1.87, 2.94), p< 0.00001). +e
subgroup analysis found that MA had absolutely
eliminate heterogeneity (I2 � 0%), while EA further
increased heterogeneity (I2 � 92%).
(c) Modeling methods: Compared with sham-acu-
puncture, verum-acupuncture had a more striking
effect in increasing platform crossover numbers in
SAMP8 (MD� 0.69, 95% CI (0.17, 1.21), p � 0.009),
APP/PS1 (MD� 1.81, 95% CI (1.56, 2.05),
p< 0.00001), ICV Aβ1–40 (MD� 1.80, 95% CI (0.65,
2.95), p � 0.002), and ICV Aβ1–42 (MD� 3.99, 95%
CI (1.70, 6.29), p � 0.0007). +e subgroup analysis
observed that both SAMP8 (I2 � 0%) and APP/PS1
(I2 � 70%) had reduced heterogeneity, while ICV
Aβ1–42 did not (I2 � 93%).
4.3.3. Time Spent in the Original Platform Quadrant.
Five studies [27, 32, 34, 37, 38] adopted time spent in the
original platform quadrant as an outcome, and all of these
studies reported a significantly better effect of verum-acu-
puncture than sham-acupuncture. Random effects model
was used for analysis due to the high heterogeneity
(p< 0.00001, I2 � 90%). As suggested, there was a remark-
able difference between verum- and sham-acupuncture
(MD� 7.28, 95% CI (4.23, 10.33), p< 0.00001) (Figure 4).
Due to the heterogeneity, we further conducted sub-
group analysis according to animal species (mice or rats),
modeling methods (SAMP8, ICV Aβ1–42, or ICV Aβ1–40),
and different acupuncture therapies (MA or EA).+e results
are indicated in Table 7.
Guo et al. 2015 6.68 10 45.99 8.58 9.6 –8.02 [–14.76, –1.28]
Lee et al. 2014 104.69 8.49 7 130.28 10.19
Li et al. 2012 24.61 15 71.34 16.15
Li et al. 2016 35.59 8 63.09 7.22
10
6
15
8
7.2
4.9
–27. 50 [–34.58, –20.42]9.3
Lin et al. 2016 49.02 4.37 10 66.81 3.93
Lin et al. 2018 65.47 5.46 12 76.64 3.77
11.6 –17.79 [–21.43, –14.15]
12 11.6 –11.17 [–14.92,–7.42]
Liu et al. 2017 56.56 2.08 10 64.08 2.16 12.4 –7.52 [–9.38,–5.66]
Luo et al. 2017 44.24 9.56 12 49.37 9.87 12 8.8 –5.13 [–12.90, 2.64]
Yu et al. 2018 54.05 6.22 8 60.99 7.67 8 9.5 –6.94 [–13.7 8, –0.10]
Zhao et al. 2013 57.3 9.58 10 73.47 10.26 10 8.2 –16.17 [–24.87, –7.47]
Zhao et al. 2017 64.68 10 12.86 10 6.8 –5.75 [–16.63, 5.13]
Total (95% CI) 112 111 100.0 –12.90 [–17.08, –8.71] 
Heterogeneity: τ 2 = 35.70; χ 2 = 61.60, df = 10 (p < 0.00001); I2 = 84% 
Test for overall effect: Z = 6.04 (p < 0.00001) –50 –25 25
Favours (verum-acupuncture)
37.97
Mean difference
IV, random, 95% CI 
Mean difference
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Sham-acupunctureVerum-acupunctureStudy or subgroup Weight(%)Mean SD Total Mean SD Total
59.22
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11.95 70.43
10
10
–25.59 [–35.89, –15.29]
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0 50 
Favours (sham-acupuncture)
Figure 2: Forest plot of verum- versus sham-acupuncture in escape latency.
Table 5: Subgroup analyses of escape latency.
Subgroup MD LL HL Df I2 Z p
Animal species
Mice −11.03 −15.31 −6.74 6 79 5.04 <0.00001
Rats −16.74 −27.74 −5.75 3 88 2.98 0.003
Acupuncture methods
MA −12.85 −20.63 −5.07 4 66 3.24 0.001
EA −12.96 −18.29 −7.63 5 90 4.77 <0.00001
Modeling
SAMP8 −9.51 −15.28 −3.73 3 26 3.23 0.001
ICV Aβ1–40 −8.03 −14.77 −1.28 — — 2.33 0.02
ICV Aβ1–42 −17.21 −37.35 2.94 1 94 1.67 0.09
APP/PS1 −12.03 −18.19 −5.86 2 92 3.82 0.0001
Intraperitoneally injected with SCO −25.59 −35.88 −15.29 — — 4.87 <0.00001
Abbreviations. MA, manual acupuncture; EA, electroacupuncture; ICV, intracerebroventricular.
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Subgroup Analyses of Time Spent in the Original Platform
Quadrant.
(a) Animal species: compared with sham-acupuncture,
verum-acupuncture evidently increased time spent
in the original platform quadrant in both mice
(MD= 5.74, 95% CI (2.06, 9.43, p � 0.002) and rats
(MD= 10.43, 95% CI (7.98, 12.87), p< 0.00001). +e
subgroup analysis observed that rats had no het-
erogeneity (I2 = 0%), while mice had a high het-
erogeneity (I2 = 93%).
(b) Acupuncture methods: compared with sham-
acupuncture, verum-acupuncture had a more re-
markable effect in prolonging time spent in the
original platform quadrant in both MA
(MD= 5.74, 95% CI (2.06, 9.43, p � 0.002) and EA
(MD= 10.43, 95% CI (7.98, 12.87), p< 0.00001).
No heterogeneity (I2 = 0%) was found in EA,
whereas marked heterogeneity (I2 = 93%) was
observed in MA.
(c) Modeling methods: compared with sham-acu-
puncture, verum-acupuncture noticeably extended
time spent in the original platform quadrant in
SAMP8 (MD=5.74, 95% CI (2.06, 9.43, p � 0.002),
ICV Aβ1–40 (MD=10.48, 95% CI (4.18, 16.79),
p � 0.001), and ICV Aβ1–42 (MD=10.42, 95% CI
(7.76, 13.07), p< 0.00001). Heterogeneity could not
be reduced via the subgroup analysis of modeling
methods.
4.3.4. Swimming Speed. +ree studies [29, 37, 38] adopted
swimming speed as an outcome. No statistical heterogeneity
was found among each study (p � 0.99, I2 � 0%), and fixed
effects model thereby was therefore used for analysis. Our
data suggested that there was no significant difference in
swimming speed between receiving verum-acupuncture and
receiving sham-acupuncture (MD� 0.03, 95% CI (–0.95,
1.01), p � 0.96) (Figure 5).
4.3.5. Other Indicators. In addition to the outcomes men-
tioned above, there were some other indicators of the Morris
water maze test also mentioned in the included studies
(Table 5). Limited to the quantity and importance, they
seemed to be not suitable for a meta-analysis but could be
synthesized with descriptive analysis.
As shown in Table 8, the percentage of time spent in
platform quadrant was reported in 2 studies [29, 39] and was
found to be increased in verum-acupuncture. Similarly,
search path length [28] and first time of crossing the plat-
form [35] were reduced in verum-acupuncture, respectively.
Number of line crossing, number of entries to the IL zone,
and total distance travelled were mentioned in only one
study [40]. Compared with sham-acupuncture, those three
outcomes were increased in verum-acupuncture [40]. All of
the above results implied the effective improvements of
acupuncture on cognitive performances among AD animals.
4.4. Sensitivity Analysis. To investigate the sources of het-
erogeneity, we performed sensitivity analysis based on the
outcome of escape latency. We chose influence analysis of
sensitivity analysis. +is process, in which one study was
removed at a time, was conducted to recalculate the com-
bined estimate on the remaining studies and evaluate the
stability of the results. We did not conduct sensitivity
analysis for the other three measures of MWM because of
the small number of studies (<10).
Figure 6 shows the results of sensitivity analysis. After
eliminating 11 studies one by one, the effect of the remaining
studies was within the 95% CI of the total effect.
4.5. Metaregression Analysis. Using escape latency as the
outcome measure, we conducted univariate metaregressions
to explore the sources of heterogeneity by treating publi-
cation year, study sample size, animal age, animal species
Table 6: Subgroup analyses of platform crossover numbers.
Subgroup MD LL HL Df I2 Z p
Animal species
Mice 1.53 1.16 1.89 4 84 8.24 <0.00001
Rats 3.29 1.47 5.11 2 91 3.55 0.0004
Acupuncture
methods
MA 0.69 0.17 1.21 1 0 2.61 0.009
EA 2.40 1.87 2.94 5 92 8.83 <0.00001
Modeling methods
SAMP8 0.69 0.17 1.21 1 0 2.61 0.009
ICV Aβ1–40 1.80 0.65 2.95 — — 3.06 0.002
ICV Aβ1–42 3.99 1.70 6.29 1 93 3.41 0.0007
APP/PS1 1.81 1.56 2.05 2 70 14.25 <0.00001
Abbreviations. MA, manual acupuncture; EA, electroacupuncture.
Guo et al. 2015 3.3 1.5 10 1.1 10 8.5 1.80 [0.65, 2.95]
Li et al. 2016 6.28 0.84 8 3.44 8 12.0 2.84 [2.13, 3.55]
Lin et al. 2016 3.2 0.46 1.08 10 14.9 2.12 [1.78, 2.46]
Lin et al. 2018 0.24 12 15.2 1.53 [1.23, 1.83]
Liu et al. 2017 2.9 0.1 1.1
1.2
0.05 10 16.1 1.80 [1.73, 1.87]
Luo et al. 2017 1.2 1.01 12 11.2 0.94 [0.14, 1.74]
Yu et al. 2018 8.38 0.79 8 1.13 8 9.9 5.18 [4.22, 6.14]
Zhao et al. 2017 2.33 10 1.82 10 0.51 [–0.17, 1.19]
80 100.0 2.01 [1.53, 2.50]
–10 –5 0 10 
80Total (95% CI)
Heterogeneity: τ 2 = 0.38; χ 2 = 80.81, df = 7 (p < 0.00001); I2 = 91% 
Test for overall effect: Z = 8.10 (p < 0.00001) Favours (verum-acupuncture)
2.67 0.48
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1.1412
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Figure 3: Forest plot of verum- versus sham-acupuncture in platform crossover numbers.
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(rats and mice), acupuncture methods (MA and EA), and
acupuncture duration as covariates. Meanwhile, multifactor
metaregressions were conducted to find the sources of
heterogeneity by taking modeling methods (SAMP8 and
APP/PS1, intraperitoneally injected with SCO, ICV Aβ1–42,
or ICV Aβ1–40) and acupoints selections as covariates. We
did not conduct metaregression according to the animal
weight due to the lack of large amounts of data, even though
we tried to contact the authors of included papers.
In metaregression, heterogeneity of escape latency could
not be substantially explained by publication year
(I2 � 80.88%, τ2 � 37.97, p � 0.195), study sample size
(I2 � 86.85%, τ2 � 35.24, p � 0.134), animal age (I2 � 77.40%,
τ2 � 36.41, p � 0.122), animal species (I2 � 83.44%,
τ2 � 44.41, p � 0.282), acupuncture methods (I2 � 85.23%,
τ2 � 50.98, p � 0.976), acupuncture duration (I2 � 84.95%,
τ2 � 50.92, p � 0.696), modeling methods (I2 � 86.85%,
τ2 � 48.72, p � 0.5093), and acupoints selections
(I2 � 85.98%, τ2 � 47.83, p � 0.4730). +ese covariates were
irrelevant to heterogeneity (Supplemental Fig. 1–6).
4.6. PublicationBiasTest. We conducted a publication bias
test for the outcome of escape latency using Egger’s test
(Pr > |z| � 0.001 < 0.05, continuity corrected) and Begg’s
test (Pr > |z| � 0.001 < 0.05, continuity corrected, Fig-
ure 7). +e potential existence of publication bias was
revealed. We did not conduct a publication bias test for
the other outcome measures because of the small number
of studies (<10).
4.7. Possible and ProposedMechanisms. +e major signaling
pathways were also investigated to gain a better under-
standing of the possible and potential mechanisms of acu-
puncture-induced cognitive improvement (Table 1).
Several signaling pathways associated with the neuro-
protective mechanisms of acupuncture were extensively
investigated in those studies, including correction of the
abnormal cerebral glycolysis metabolism [36, 39], en-
hancement of synaptic plasticity [34, 35, 38], antiapoptosis
and repair of neuronal cells [27, 38], degradation and de-
creases of Aβ protein deposits [34, 39], upregulation of the
hippocampal expression of BDNF [28, 29, 33] and TrkB [33],
and reduction of neuron loss and apoptosis [32].
Acupuncture therapy was also shown to attenuate the
AD-induced cognitive impairments via upregulating the
stabilisation of the cellular signal [37] but downregulating
GSK-3β [34] or negative regulation of neuroinflammation
[40].
5. Discussion
5.1. Summary of Findings. To the best of our current
knowledge, it is the first systematic metaanalysis investi-
gating the effectiveness of verum-acupuncture on AD ani-
mal models compared with sham-acupuncture with the
results of the Morris water maze test as the outcome
assessment.
We found low to moderate level of evidence that verum-
acupuncture had a superior effect in reducing escape latency,
increasing platform crossover numbers, and time spent in
the original platform quadrant when compared with sham-
acupuncture. However, no significant difference in swim-
ming speed between two therapies was observed. +e
findings suggest that acupuncture may have a neuro-
protective effect in animal models of AD, and this benefit is
more than just a placebo effect.
5.2. Comparison with Other Reviews. Park et al. published
the first review on the effect of acupuncture on AD in
animal-based research in 2017 [44]. According to Park’s
review, MA and EA appeared to generate similar benefits
to AD rodents when targeted the same acupoints [44].
One limitation of Park’s review is that it included two
studies without any experiment and assessment for
animal behaviors. Furthermore, most of the studies Park
et al. included only involved a comparison between
Guo et al. 2015 23.25 8.94 10 4.85
Li et al. 2012 20.18 2.03 15 12.18 1.14
Luo et al. 2017 20.2 4.2 12
Yu et al. 2018 34.19 2.45 8 23.77 2.94
Zhao et al. 2017 20.15 1.3 10 17.37 2.09
55Total (95% CI)
Heterogeneity: τ 2 = 9.82; χ 2 = 38.94, df = 4 (p < 0.00001); I2 = 90% 
Test for overall effect: Z = 4.68 (p < 0.00001)
10 12.0 10.48 [4.18, 16.78] 
15 23.8 8.00 [6.82, 9.18] 
12 20.3 6.49 [3.63, 9.35] 
8 20.8 10.42 [7.77, 13.07] 
10 23.2 2.78 [1.25,4.31]
55 100.0 7.28 [4.23, 10.33] 
–50 –25 0 25 
Favours (verum-acupuncture)  Favours (sham-acupuncture)
50 
Mean difference
IV, random, 95% CI
Mean difference
IV, random, 95% CI
Sham-acupunctureVerum-acupunctureStudy or subgroup Weight(%)SDMean Total SDMean Total
13.71 2.81
12.77
Figure 4: Forest plot of verum- versus sham-acupuncture in time spent in the original platform quadrant.
Table 7: Subgroup analyses of time spent in the original platform
quadrant.
Subgroup MD LL HL Df I2 Z p
Animal species
Mice 5.74 2.06 9.43 2 93 3.05 0.002
Rats 10.43 7.98 12.87 1 0 8.36 <0.00001
Acupuncture
methods
MA 5.74 2.06 9.43 2 93 3.05 0.002
EA 10.43 7.98 12.87 1 0 8.36 <0.00001
Modeling methods
SAMP8 5.74 2.06 9.43 2 93 3.05 0.002
ICV Aβ1–40 10.48 4.18 16.79 — — 3.26 0.001
ICV Aβ1–42 10.42 7.76 13.07 — — 7.70 <0.00001
Abbreviations. MA, manual acupuncture; EA, electroacupuncture; ICV,
intracerebroventricular.
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acupuncture and wait-list control. +e lack of an effective
placebo- or sham-acupuncture control reduces the val-
idity of the results. No meta-analysis was included in that
review as well [44]. Our subgroup analysis suggests that
the effect of EA seemed slightly better than MA. +is is
likely because we included more persuasive studies in the
review.
5.3. Sources ofHeterogeneities. +ehigh heterogeneities were
found among the studies. We thereby conducted the
subgroup analysis to identify the source of heterogeneities.
Subgroup classification was based on animal species,
modeling methods, and acupuncture methods. It is en-
couraging to note that, after subgroup analysis, effects of
acupuncture on AD animals remained positive, and het-
erogeneity was partially well-explained. For instance,
verum-MA could increase platform crossover numbers in
SAMP8 mice models compared with sham-MA (MD� 0.69,
95% CI (0.17, 1.21), p � 0.009, I2 � 0%). However, the het-
erogeneities among the studies based on escape latency and
time spent in the original platform quadrant could not be
Guo et al. 2015 2.45 10
Lee et al. 2014 24.82
17.74 17.69
Luo et al. 2017 1.16 12
29Total (95% CI) 
Heterogeneity: χ 2 = 0.01, df = 2 (p = 0.99); I2 = 0% 
Test for overall effect: Z = 0.05 (p = 0.96) 
8.61
2.25 10
6.05
1.63
28
0.05 [–2.01, 2.11] 
2.5
74.9
0.03 [–0.95, 1.01] 
–20
Favours (experimental) Favours (control) 
20 
Mean difference
IV, fixed, 95% CI
Mean difference
IV, fixed, 95% CI
Sham-acupunctureVerum-acupunctureStudy or subgroup Weight(%)Mean SD Total Mean SD Total
8.64
5.33 25.137 6
12
22.6
–0.31 [–6.56, 5.94]
0.03 [–1.10, 1.16]
100.0
–10 0 10
Figure 5: Forest plot of verum- versus sham-acupuncture in swimming speed.
Table 8: Other outcomes of the Morris water maze.
Other outcomes of the Morris water maze Included studies Compared with the sham-acupuncture group
Percentage of time spent in platform quadrant [29, 39] +
Search path length [28] −
First time of crossing the platform [35] −
Number of line crossing [40] +
Number of entries to the IL zone [40] +
Total distance travelled [40] +
 −2.77  −1.83 −2.55  −1.11  −0.94
Zhao et al. (2017)
 Lin et al. (2016)
 Lee et al. (2014)
 Li et al. (2012)
 Lin et al. (2018)
 Yu et al. (2018)
 Li et al. (2016)
Zhao et al. (2013)
 Luo et al. (2017)
 Guo et al. (2015)
 Liu et al. (2017)
Lower CI limit
Estimate
Upper CI limit
 Meta-analysis estimates, given named study is omitted
Figure 6: Sensitivity analysis on the outcome of escape latency.
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completely clarified despite further sensitivity analyses and
metaregression analyses.
5.4. Potential Mechanisms. +e underlying mechanisms
linking acupuncture and the treatment of AD were
partially summarized in our result section. In addition to
the proposed mechanisms listed in Table 1, we identified
three relevant review papers, including one systematic
review without meta-analysis [45] and two narrative
reviews [44, 46]. According to the review by Leung et al.
[45] and Cao et al. [46], acupuncture could alleviate
cognitive impairments by modulating multiple signaling
pathways involved in neuroprotection and neurorepair.
For instance, promotion of cholinergic neural trans-
mission is one of the main mechanisms of acupuncture,
including alleviation of the loss of hippocampal acetyl-
cholinesterase (AChE) immunoreactivity [45, 47] and
elevation of the activity of hippocampal choline acetyl-
transferase (ChAT) [45, 48]. Similarly, acupuncture in-
creases activity of hippocampal triosephosphate
isomerase (TPI) [36], deficiency of which may suppress
the process of glycolysis and eventually leads to de-
generation of cerebral functions [46, 49]. Both inhibition
of oxidative stress and attenuation of neuronal apoptosis
contribute the therapeutic mechanisms of acupuncture
as well [45, 46]. Acupuncture primarily suppress the
oxidative stress and the subsequent cell death triggered
by oxidative damage via minimizing the damages of
neuronal mitochondria in the hippocampus [45, 46]. A
significant decline of dying neurons was detected in the
hippocampus of AD rodent undergoing real-acupunc-
ture compared with the sham-acupuncture control
[46, 50].
5.5. Challenge and Implications. +e results from our study
appear to be promising, and it is however too early to draw
any definitive and positive conclusion. +ere are several
challenges impacting on translating preclinical evidence into
clinical evidence.
Firstly, the results of our systematic review show that
acupuncture has the potential to improve cognitive im-
pairments in AD, and this finding is consistent with re-
sults of a few clinical trials, which also report that
acupuncture improves quality of life of AD patients
[51–53]. +e therapeutic effect was enhanced by combined
acupuncture and oral administration of conventional
medication such as huperzine A capsules [52]. However,
methodological problems from both clinical trials and
animal experiments impact on the strength of evidence.
More randomized clinical trials with better study designs
thereby are needed.
Secondly, in view of Table 1, acupuncture is found to
attenuate cerebral injuries through multiple mechanisms.
Details of the critical mechanisms closely associated with
cognitive functions are insufficient at present. For instance,
it is unclear how acupuncture improves on systemic- and
neuroinflammation, oxidative stress, and synaptic plasticity
among ADmodels. Once biomarkers are identified, they can
be used in future clinical studies.
+irdly, the acupuncture protocols used in the included
studies are heterogenous. Some studies applied a set of
acupoints [27, 32, 36, 37, 40], while others stimulated one
acupoint only [28, 33, 39]; three studies intervened for 28
days [28, 33, 38], while other six studies only took half of the
time [27, 29, 32, 34, 35, 40]. +e following questions
remained to be answered: Does the selection of acupoints
(more or less) or/and the intervention duration directly
affect the effects of acupuncture on AD-induced cognitive
Begg’s funnel plot with pseudo 95% confidence limits
SM
D
s.e. of SMD
0 0.5 1
–4
–2
0
Figure 7: Begg’s publication bias test of escape latency.
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dysfunction? How big is this effect? After all, how to organize
the least number of acupoints to achieve the best therapeutic
effect is of great value to reduce the cost of clinical practice.
Finally, clinically, acupuncture is applied based on the
basic theory of TCM, which emphasizes the concept of
“syndrome types” [54]. “Treatment based on syndrome
differentiation” (TBSD) is the core principle of TCM; that is,
patients are classified into different TCM syndrome types
according to their clinical signs and symptoms and then
corresponding treatments are prescribed [54, 55]. Briefly,
AD patients with different syndrome types are usually given
different acupuncture prescriptions in clinical practice
[56, 57]. Unfortunately, in the studies we retrieved, TBSD
was usually ignored even though the AD animal modeling
methods were varied. Establishing different AD models
based on syndrome types, and then verifying the efficacy of
acupuncture prescriptions in these models, seems to bemore
in line with the laws of TCM research and might make the
findings from the preclinical research more relevant to
clinical practice.
6. Limitations
Our systematic review and meta-analysis have several lim-
itations. Firstly, the total number of studies and the total
sample size were relatively small. Secondly, we did not in-
clude other acupuncture techniques such as laser and au-
ricular acupuncture. +irdly, the quality of included studies
was unsatisfactory. Among the included researches, one
study scored points in seven items [39], four studies in six
items [29, 33, 35, 37], and the reminding studies only in five
items according to ‘SYRCLE’s bias tool [31]. +e reasons for
the low quality of most studies were mainly due to (1)
unclear states of baseline comparability and randomization
methods of allocation and (2) absence of blinding methods
and random selection for outcome evaluation. Our results
also indicated that there was a publication bias. Further
rigorous and well-designed animal studies with larger
sample sizes are required.
7. Conclusions
Acupuncture might be effective in ameliorating cognitive
dysfunction in AD animals, and this benefit is more than just
a placebo effect. Furthermore, our findings implies that the
neuroprotective effects of acupuncture might be achieved
through blocking the apoptosis and loss of neuronal cells,
correcting of the abnormal cerebral glycolysis metabolism,
enhancing of synaptic plasticity, degrading and decreasing of
Aβ deposits, and upregulating of the hippocampal expres-
sion of BDNF. However, these findings should be inter-
preted cautiously due to the limitations of the included
studies.
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